- Previous Close
20.30 - Open
20.30 - Bid 19.17 x 800
- Ask 20.28 x 800
- Day's Range
19.46 - 20.34 - 52 Week Range
15.15 - 25.64 - Volume
1,680,303 - Avg. Volume
2,012,284 - Market Cap (intraday)
3.351B - Beta (5Y Monthly) 1.31
- PE Ratio (TTM)
-- - EPS (TTM)
-7.82 - Earnings Date Feb 5, 2025 - Feb 10, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
21.42
Envista Holdings Corporation, together with its subsidiaries, develops, manufactures, markets, and sells dental products in the United States, China, and internationally. The company operates in two segments, Specialty Products & Technologies, and Equipment & Consumables. The Specialty Products & Technologies segment offers dental implant systems, guided surgery systems, biomaterials, and prefabricated and custom-built prosthetics to oral surgeons, prosthodontists and periodontists, and general dentist; and brackets and wires, tubes and bands, archwires, clear aligners, digital orthodontic treatments, retainers, and other orthodontic laboratory products. This segment also provides software packages, which include DTX Studio Implant; DTX Studio Lab; and DTX Studio Clinic, a software package offered with its imaging products. It offers its products under the Nobel Biocare, Alpha-Bio Tec, Implant Direct, Nobel Procera, Ormco, Spark, Orascoptic, Damon, Insignia, AOA brands. The Equipment & Consumables segment provides dental equipment and supplies, including digital imaging systems, software, and other visualization/magnification systems; endodontic systems and related products; restorative materials, rotary burs, impression materials, bonding agents, and cements; and infection prevention products. This segment offers its products under the Dexis, DTX Studio, Kerr, Metrex, Total Care, Pentron, Optibond, Harmonize, Sonicfill, Sybron Endo, and CaviWipes to dental offices, clinics, and hospitals. Envista Holdings Corporation was incorporated in 2018 and is headquartered in Brea, California.
envistaco.com12,800
Full Time Employees
December 31
Fiscal Year Ends
Sector
Medical Instruments & Supplies
Industry
Recent News: NVST
View MorePerformance Overview: NVST
Trailing total returns as of 12/13/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: NVST
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: NVST
View MoreValuation Measures
Market Cap
3.35B
Enterprise Value
3.93B
Trailing P/E
--
Forward P/E
15.48
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
1.34
Price/Book (mrq)
1.09
Enterprise Value/Revenue
1.57
Enterprise Value/EBITDA
24.09
Financial Highlights
Profitability and Income Statement
Profit Margin
-53.42%
Return on Assets (ttm)
1.69%
Return on Equity (ttm)
-36.31%
Revenue (ttm)
2.5B
Net Income Avi to Common (ttm)
-1.34B
Diluted EPS (ttm)
-7.82
Balance Sheet and Cash Flow
Total Cash (mrq)
991.3M
Total Debt/Equity (mrq)
51.26%
Levered Free Cash Flow (ttm)
351.05M